Loading
Latest filing published 23 Feb 2023 for Finch Therapeutics Group, Inc., €1,643.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Marc Blaustein, listed as senior executive, appears in our data through filings on Finch Therapeutics Group, Inc. shares, published by SEC (Form 4). The record holds 3 filings, for trades running from 13 June 2022 to 21 February 2023.
Every open-market trade on record is a sale: 2 sales worth €6,811. Besides market trades, the filings include 1 share grant. In 2023 alone, the filings show no purchases and 1 sale.
The newest entry dates from 23 February 2023: an open-market sale of €1,643, in Finch Therapeutics Group, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations